DiRaimondo Thomas 4
4 · Janux Therapeutics, Inc. · Filed Jan 3, 2025
Insider Transaction Report
Form 4
DiRaimondo Thomas
Chief Scientific Officer
Transactions
- Award
Common Stock
2025-01-02+24,000→ 129,719 total - Award
Stock option (right to buy)
2025-01-02+84,000→ 84,000 totalExercise: $53.24Exp: 2035-01-01→ Common Stock (84,000 underlying)
Footnotes (3)
- [F1]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
- [F2]Includes 497 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,327 shares acquired under the Plan on May 13, 2022, 1,130 shares acquired under the Plan on November 15, 2022, 1,715 shares acquired under the Plan on May 15, 2023, 763 share acquired under the Plan on November 15, 2023, 1,406 shares acquired under the Plan on May 15, 2024 and 943 shares acquired under the Plan on November 15, 2024.
- [F3]25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.